Within the category of diseases of the urogenital system, the G-BA includes diseases such as the urge to urinate as well as preparations for use following a kidney transplant. So far XX different medicinal products have been assessed in XX procedures. A major additional benefit has been displayed for xx%, considerable additional benefit for XX% and minor additional benefit for XX% of the patient populations in question. A non-quantifiable additional benefit in relation to the comparative therapy has been proved for XX% of the subpopulations.

An additional benefit in relation to the comparative therapy has not been proved for XX% of the subpopulations as weighted according to their share of patients in the respective resolution. These subpopulations comprise xx% of the maximum of all xx million patients suitable for treatment with the evaluated medicinal products who do not actually benefit from them.